KG Pharma Limited/科志康医药科技有限公司

KG Pharma Limited, founded in 2016, is located in Shanghai and Foshan. KG is a pioneering consulting corporation in China focused on drug research and development. KG has originally developed VIMC model to improve drug research efficiency. KG’s mission is to help clients streamline process management and accelerate regulatory approvals of drug research and development. To solve the issues of labor recruitment and layoffs, KG has originally developed VIMC model to economize human resource, on which management team in Biotechs from PCC to IND submission will be replaced by the service of Project Management. The service is highly modularized, standardized and flow-schemalized so that Biotechs can acquire the capability cheaply and flexiblely to achieve IND submission. Via buying project management service, Biotechs no longer have troubles in labor management including recruitment, skillful training, dismission, layoffs and legal risks. For each IND project, Biotechs can also save at least USD $1 million and 12 months. KG has published 700+ deep insights in KG’s website and wechat about NDA/BLA case studies by FDA, EMA and NMPA, including chemicals, biologcis, and cellular and gene therapies. Based on regulatory evaluation database, KG can provide more stable service of regulatory consulting and submission compared to traditional expert-based consulting. In addition, KG has KG Forum, a monthly serial symposium focusing on the frontier, hot topics and bottlenecks of drug research and development. Over 120 forums has been held or co-held since 2016. KG has established the collaborations with over 200 pharmaceutical and biotech companies, and successfully achieved the approvals of 100+ INDs, 6 NDAs and 8 ANDAs by NMPA, 1 NDA by FDA.